AEON Biopharma Inc
aeonbiopharma.comWhat Do They Do?
Develops a proposed Botox biosimilar for therapeutic treatment of debilitating medical conditions.
Who Are Their Customers?
Targets healthcare providers who purchase and administer botulinum toxin products in a physician-administered, buy-and-bill market; its development program is focused on therapeutic indications.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$1.2MView ↗
- ▼ −83% (Loss)
- vs −$6.6M in Q2 FY2025
From blank-check company to drug developer
The older report describes a blank-check company seeking a medical-technology business combination; the latest describes a biopharmaceutical company developing a Botox biosimilar for therapeutic use.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Mar 30, 2026We are a biopharmaceutical company focused on developing ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) for therapeutic…View ↗
Loading...
